Capecitabine Adamed

Quick links

Choose a section

Quick links to important sections

Advertisements

Capecitabine Adamed

Advertisements
Advertisements

Overview of Capecitabine Adamed

Property Description
Active ingredient Capecitabine
Form Film-coated tablet
Pharmacological class Antineoplastic agent, Fluoropyrimidine carbamate
General purpose To control the growth of rapidly dividing cells
Origin Synthetic organic compound; Prodrug

What Type of Medicine is Capecitabine Adamed?

Capecitabine Adamed, manufactured by Adamed, is a prescription-only medicine classified as an antineoplastic agent that belongs to the pharmacological class of fluoropyrimidine carbamates. This systemic drug is defined as a synthetic cytotoxic medicine and is recognized as an antimetabolite, meaning its core function is to interfere with the metabolic processes essential for cellular growth.

Its classification places it among specialized drugs clinically recognized for managing conditions characterized by the rapid and uncontrolled proliferation of abnormal cells. Its function is primarily systemic, and it is utilized as a single active ingredient product, ensuring focused therapeutic action under the trade name Capecitabine Adamed.

Composition, Form, and Origin of Capecitabine

The active substance in this preparation is Capecitabine (INN), a fully synthetic organic compound that is not derived from natural sources. The medicine is supplied for oral administration in the specific film-coated tablet dosage form, containing the active ingredient within a solid pharmaceutical base.

This oral formulation was developed to provide a therapeutic alternative to its precursor, 5-fluorouracil (5-FU), which traditionally required intravenous infusion. The tablet form allows the Capecitabine compound to be absorbed through the digestive tract for consistent systemic administration.

Why is Capecitabine Classified as a Prodrug?

Capecitabine is classified as an oral prodrug because it is administered in an inactive state and must undergo an enzymatic conversion process within the body to release the therapeutically effective substance, 5-fluorouracil.

This prodrug design is integral to the medicine’s general therapeutic purpose: to control cell proliferation. The activation is engineered to occur preferentially within tumor tissues—a concept known as tumor-selective activation—which aims to maximize the local concentration of the cytotoxic medicine where the cell growth is most rapid. This mechanism characterizes the drug's established therapeutic approach.

Advertisements

What side effects are possible with Capecitabine Adamed?

Possible side effects and safety information

Official regulatory documents classify the medicine’s adverse reactions based on frequency and the affected body system, providing a framework for understanding the drug's safety profile.


Frequency-Classified Adverse Reactions

The safety profile includes events documented as Very Common (ge 10%) which primarily involve the gastrointestinal system and skin. These often include severe diarrhea, stomatitis (inflammation of the mouth), nausea, vomiting, abdominal pain, and Palmar-Plantar Erythrodysesthesia Syndrome (Hand-Foot Syndrome). Common (1% to <10%) events include general effects like fatigue, fever, and dehydration, alongside mild myelosuppression (e.g., anemia).


Serious Adverse Reactions and Safety Constraints

The official labeling notes that life-threatening or fatal toxicities can occur in individuals with a known complete Dihydropyrimidine Dehydrogenase (DPD) deficiency; therefore, the medicine is contraindicated in this population. Serious cardiac disorders, including myocardial infarction and cardiac failure, are also documented as potential risks. The use of Capecitabine is strictly contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min).

For older adults (ge 60 years), there is a noted increased risk of severe bleeding when the medicine is used concomitantly with oral Vitamin K Antagonists.

These safety classifications, organized into categories such as Gastrointestinal disorders and Skin and subcutaneous tissue disorders, establish the official risk expectations and mandatory usage limitations for the medicine.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Capecitabine Adamed

Official regulatory documents specify that Capecitabine overexposure can lead to severe or life-threatening toxicity. Documented manifestations of overdose primarily affect the body’s essential systems.

Documented Overdose Manifestations

  • Gastrointestinal: Acute, severe diarrhea, painful inflammation of the mouth and digestive tract (mucositis), nausea, and vomiting.
  • Hematologic/Systemic: Myelosuppression (leading to neutropenia and signs of infection), neurotoxicity, and severe dehydration, which can result in acute renal failure.
  • Severe Outcomes: Cardiotoxicity is a documented severe outcome.

Emergency Response and Antidote

  • Immediate medical help must be sought for any known overexposure, regardless of the presence of symptoms. Urgent treatment is also required if early-onset, severe or life-threatening toxicity develops within 96 hours of the last dose.
  • The specific emergency treatment approved by the FDA is Uridine Triacetate. This antidote is indicated for adult and pediatric patients for the early management of severe toxicity or overdose.

Population-Specific Risk

  • Patients with low or absent Dihydropyrimidine Dehydrogenase (DPD) enzyme activity are identified as being at a significantly increased risk for acute, severe, and potentially fatal adverse reactions. Regulatory guidance states that no safe dose has been established for individuals with a complete absence of DPD activity.
Advertisements

Therapeutic Uses of Capecitabine Adamed

What Capecitabine Adamed Treats: Main Uses and Benefits

This medication is commonly used for managing specific types of solid tumors, including cancers of the colon/rectum, breast, and stomach. The primary goal is to help with managing the condition's activity, which may assist with the patient's overall support and comfort.

The medicine is often used as part of a long-term treatment plan in clinical settings that involve chronic or recurrent disease. It is applied when supportive symptom management may be appropriate.

By addressing the disease's activity, this medication may assist with lessening issues caused by the tumor's presence and helps manage symptoms related to systemic imbalance and physical discomfort. This may assist with addressing symptoms that interfere with daily functioning, such as fatigue.

“It is commonly used across domains where additional symptomatic support is needed.”


Quick Fact: Relief for Symptom Clusters

This treatment is relevant for easing symptoms that may become disruptive or intense, which may assist patients in coping with symptom fluctuations.

Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Capecitabine Adamed? — Official Regulatory Information

Capecitabine use is strictly defined by government regulatory documents, which establish criteria for contraindication and restricted use based on the patient’s clinical and metabolic status.

Populations for Whom Use is Contraindicated (Must Not Use)

  • Hypersensitivity: Patients with known allergy to capecitabine, 5-fluorouracil (5-FU), or any component of the formulation.
  • Severe Metabolic Deficiency: Patients with a known complete absence of Dihydropyrimidine Dehydrogenase (DPD) activity are at risk of severe, potentially fatal toxicity. No safe dose has been established.
  • Organ Dysfunction: Patients with severe renal impairment (creatinine clearance below 30, mL/ min).
  • Hematologic Status: Individuals with severely low baseline neutrophil counts (< 1.5 imes 10^9/ L) or thrombocyte counts (< 100 imes 10^9/ L).
  • Pregnancy and Lactation: Use is contraindicated during pregnancy (due to potential fetal harm) and breastfeeding.

Populations Requiring Restricted or Conditional Use

  • Partial DPD Deficiency: Patients with reduced DPD activity may be considered for treatment but require close monitoring and may need a reduced starting dose.
  • Organ Impairment: Patients with moderate renal impairment ( CrCl, 30-50, mL/ min) require a reduced starting dose. Patients with mild-to-moderate hepatic impairment must be closely monitored.
  • Age-Related Rules: The safety and effectiveness have not been established in the pediatric population (under 18 years of age). Elderly patients, especially those over 80 years, require close monitoring due to increased sensitivity to adverse effects.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Capecitabine Adamed's interaction profile is structured by specific pharmacological and metabolic constraints documented by regulatory authorities.

Contraindicated Combinations

Use is contraindicated in patients with a known complete or near-complete absence of the enzyme Dihydropyrimidine Dehydrogenase (DPD), a severe metabolic vulnerability that prevents clearance of the active metabolite, 5-fluorouracil. Co-administration is also contraindicated in individuals with severe renal impairment (creatinine clearance < 30 mL/min) due to altered drug clearance and heightened toxicity risk.


Official Pharmacological and Exposure Interactions

Interacting Agent Official Interaction Outcome
Vitamin K Antagonists (VKAs) (e.g., Warfarin) Causes a clinically significant increase in Prothrombin Time (PT) and International Normalized Ratio (INR), raising the risk of severe bleeding. Frequent monitoring and dose adjustment of the VKA are required.
Leucovorin (Folates) Increases the concentration of 5-fluorouracil (the active metabolite), which may result in enhanced toxicity.
Phenytoin Increases the plasma levels of co-administered Phenytoin.
Food Reduces both the rate and extent of Capecitabine absorption, decreasing the parent drug's plasma concentration (Cmax) by approximately 60% and its total exposure (AUC) by 35%.

Official Restrictions and Cautions

The regulatory label advises that the use of Allopurinol should be avoided during treatment. Caution should also be exercised when Capecitabine is co-administered with CYP2C9 substrates. Furthermore, patients with mild to moderate hepatic impairment are noted to exhibit altered pharmacokinetics, specifically an increased Cmax of the parent drug.

Advertisements

Mechanism of Action

Mechanism 1: The Three-Step Prodrug Activation

Capecitabine is an inactive compound that must first undergo three sequential enzymatic conversions inside the body, a process that relies on enzymes like Thymidine Phosphorylase (TP). This process is a required step for the subsequent molecular action to occur, transforming the inactive molecule into the cytotoxic agent, 5-fluorouracil (5-FU). The final activation step occurs preferentially in cell populations where TP concentration is higher. This results in a higher concentration of the active molecule in certain tissues.


Mechanism 2: Irreversible Blockade of DNA Synthesis

The activated form of the drug works as an antimetabolite, forming an intermediate ( 5-FdUMP) that attaches permanently to the critical enzyme Thymidylate Synthase (TS). This irreversible inhibition blocks the production of dTMP, a crucial building block required for DNA replication. This action causes a metabolic depletion of the necessary building blocks for new DNA strands, creating a state of metabolic stress and imbalance in the cell's nucleotide pool.


Mechanism 3: Cellular Damage and Programmed Cell Death

By depleting DNA components and causing RNA metabolites to be misincorporated into the cellular machinery, the mechanism creates structural and metabolic damage. This failure of replication and protein synthesis triggers apoptosis (programmed cell death) in the highly proliferative cells. The mechanism induces cellular death ( apoptosis) within the rapidly proliferating cell populations, resulting in the inhibition of cellular growth. This physiological effect represents the direct consequence of the drug's molecular action.

Advertisements

Dosage and Administration Information

How Capecitabine Adamed is Used: Administration Guidelines

Capecitabine Adamed is an oral medicine administered as film-coated tablets in strengths of 150 mg and 500 mg. The administration of the medicine involves specific parameters regarding dosing, timing, and schedule.

Dosing and Schedule

The dosage is calculated according to the patient’s Body Surface Area (BSA), and the total dose is rounded to the nearest 150 mg increment to ensure administration using whole tablets.

Standard regimens typically involve a 21-day cycle with the following pattern:

  • Dosing: The medicine is taken twice daily (morning and evening), approximately 12 hours apart.
  • Duration: The dose is administered for 14 consecutive days (Days 1–14), followed by a mandatory 7-day rest period (Days 15–21).
  • Course: Adjuvant treatment may be prescribed for a fixed duration, such as a maximum of 8 cycles, while metastatic treatment continues until progression.

Administration Conditions

To ensure proper use, specific conditions are followed:

  • With Food: The tablets must be taken with food or within 30 minutes after a meal.
  • Preparation: Tablets must be swallowed whole with water. They must not be crushed, cut, or chewed.
  • Missed Dose: If a dose is missed or vomited, the standard procedure is to skip the missed dose and continue with the next scheduled dose; no extra dose is taken to compensate.
Advertisements

Recent Clinical Evidence

Capecitabine Adamed: Recent Clinical Evidence

Clinical research on capecitabine, the active ingredient in Capecitabine Adamed, centers on its use as a chemotherapy agent for various solid tumors, including colorectal and breast cancers. Studies primarily investigate two key areas: its efficacy in different treatment settings and ongoing efforts to optimize its safety profile.


Investigating Treatment Efficacy

Capecitabine acts as an oral prodrug that is converted by enzymes in the body into the active chemotherapy agent 5-fluorouracil (5-FU). Research has focused on its role in both early and metastatic disease, often comparing its use as a single agent versus in combination regimens.

  • Monotherapy: Studies in patients with metastatic breast cancer who had previously received anthracycline and taxane regimens showed that capecitabine monotherapy was associated with certain response rates and median survival times.
  • Combination Therapy: Trials have examined combining capecitabine with other agents, such as taxanes (e.g., docetaxel or paclitaxel). For metastatic breast cancer, some combination studies have demonstrated associations with improved response rates and time to disease progression when compared to the taxane used alone.

Safety and Pharmacogenomic Research

Recent research and regulatory updates have emphasized pharmacogenomic safety, particularly concerning the enzyme dihydropyrimidine dehydrogenase (DPD).

  • DPD Deficiency: DPD is critical for breaking down capecitabine's active metabolite (5-FU). A deficiency in this enzyme, caused by certain DPYD gene variants, may lead to an increased risk of severe, potentially life-threatening toxicity.
  • Regulatory Updates: Regulatory bodies, including the US Food and Drug Administration (FDA), have updated prescribing information to strongly recommend or require DPYD genetic testing before initiating capecitabine treatment, except in cases where immediate therapy is necessary. This reflects the growing body of evidence supporting personalized dosing based on genetic status to mitigate adverse event risk.
  • Tolerability: Common adverse events monitored in clinical trials include Hand-Foot Syndrome (HFS), diarrhea, and nausea. Research continues to explore alternative dosing schedules and supportive care methods to improve patient tolerability and reduce the need for dose modifications.

Key Studies & References

  1. FDA Updates Capecitabine Label to Require Pre-Treatment DPYD Genetic Testing (Updated Prescribing Information)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Capecitabine Adamed (FAQ)

Q: Does Capecitabine Adamed treat other conditions besides the main ones?

According to the official product information, this medicine is approved for various uses, primarily for different types of colorectal and breast cancer. Regulatory bodies, such as the FDA, have updated the drug’s labeling over time to reflect a complete list of all approved uses. The official prescribing information contains the latest approved indications.

Q: Does Capecitabine Adamed cause hair loss in most people?

Official adverse event listings indicate that hair loss, known medically as alopecia, is a documented adverse effect associated with Capecitabine treatment. This adverse effect is listed with a frequent occurrence rate in official documents.

Q: Can Capecitabine Adamed interact with common over-the-counter pain relievers?

Official drug interaction guides indicate that certain common anti-inflammatory medications, such as ibuprofen, naproxen, or aspirin, may increase the chance of bleeding or interfere with the chemotherapy. Regulatory information states that use of these over-the-counter pain relievers should be discussed with a healthcare provider.

Q: What types of vitamins or supplements might interfere with Capecitabine Adamed?

Regulatory warnings mention that various natural health products, vitamins, and dietary supplements can potentially interfere with the drug's intended action or increase the risk of adverse effects. Official warnings caution that all supplements and vitamins should be discussed with a healthcare provider before starting treatment.

Q: How does Capecitabine Adamed interact with alcohol?

Official drug safety information classifies the combination of Capecitabine and alcohol as a major interaction risk. Regulatory guidance states that consumption of alcohol during treatment should be discussed with a healthcare professional.

Q: Does Capecitabine Adamed affect the contraception used by patients?

The official label includes a requirement for females who can become pregnant to use effective contraception during the treatment period and for a specified time after the last dose, as the drug can harm an unborn fetus. Males with female partners are also cautioned regarding the use of effective contraception.

Q: What are the official regulatory approvals for Capecitabine Adamed?

The drug, Capecitabine Adamed, is officially approved for use by major regulatory bodies globally, including the FDA in the United States and the EMA in Europe. Its labeling and prescribing information, which cover approved uses and safety rules, are routinely updated based on new scientific evidence.

Q: Has Capecitabine Adamed been studied in combination with radiation therapy?

Yes, official regulatory labeling includes instructions for the drug’s use as a component of chemoradiotherapy, which is the combination of chemotherapy with radiation. This type of combined treatment is used for certain cancers, such as locally advanced rectal cancer.

Q: What should a patient do if they feel sick after taking Capecitabine Adamed?

Official safety guides include a recommendation to contact the hospital or care team immediately if a patient begins to feel unwell, develops a fever, or experiences signs of severe side effects like blistering or severe diarrhea.

Q: Can Capecitabine Adamed cause sun sensitivity?

Yes, official adverse event profiles indicate that the drug can cause increased sensitivity of the skin to sunlight, also known as photosensitivity. The official warnings indicate that necessary precautions against sun exposure are required during treatment.

Q: Does Capecitabine Adamed affect fertility in men or women?

Official safety warnings indicate that fertility may be impaired by the drug. This finding is based on evidence from animal studies.

Q: What information is available about Capecitabine Adamed's effect on taste?

Official adverse event listings for this class of drug document that taste disorders, also called dysgeusia, are a potential oral side effect. This refers to changes in or a complete loss of the normal sense of taste.

Advertisements

How should Capecitabine Adamed be stored and disposed of?

Storage and Disposal Requirements for Capecitabine

Capecitabine tablets, a cytotoxic medicine, require specific storage and disposal protocols as defined by regulatory labeling.


Storage Conditions

Requirement Official Regulatory Statement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68F to 77F), and not exceeding 30C.
Protection Store in a dry place and away from light.
Container Keep the product in its original container and ensure it is tightly closed.
Child Safety Keep the medicine out of the reach and sight of children and pets.

Handling and Disposal

As a cytotoxic agent, capecitabine requires special handling. Tablets must not be cut, crushed, or chewed to avoid exposure, and any person handling the medication should exercise caution. Unused or expired capecitabine must not be flushed down the toilet or thrown in the household trash. Disposal must occur via an approved drug take-back program or through specialized pharmaceutical waste procedures, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Capecitabine Adamed found in:

A-Z Index: